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Resistance to thyroid hormone b (RTHb) due to homozygous THRB defects is exceptionally rare, with
only five kindreds reported worldwide. Cardiac dysfunction, which can be life-threatening, is rec-
ognized in the disorder. Here we describe the clinical, metabolic, ophthalmic, and cardiac findings in a
9-year-old boy harboring a biallelicTHRBmutation (R243Q), along with biochemical, physiologic, and
cardiac responses to carbimazole and triiodothyroacetic acid (TRIAC) therapy. The patient exhibits
recognized features (goiter, nonsuppressed thyroid-stimulating hormone levels, upper respiratory
tract infections, hyperactivity, low body mass index) of heterozygous RTHb, with additional char-
acteristics (dysmorphic facies, winging of scapulae) and more markedly elevated thyroid hormone
levels, associated with the homozygous form of the disorder. Notably, an older sibling with similar
clinical features and probable homozygous RTHb had died of cardiac failure at age 13 years. Features
of early dilated cardiomyopathy in our patient prompted combination treatment with carbimazole and
TRIAC. Careful titration of therapy limited elevation in TSH levels and associated increase in thyroid
volume. Subsequently, sustained reduction in thyroid hormones with normal TSH levels was reflected
in lower basal metabolic rate, gain of lean body mass, and improved growth and cardiac function. A
combination of antithyroid drug and TRIAC therapy may prevent thyrotoxic cardiomyopathy and its
Abbreviations: ERG, electroretinogram; FT4, free thyroxine; LV, left ventricular; MRI, magnetic resonance imaging; NT proBNP, N-
terminal pro B-type natriuretic peptide; RTHb, resistance to thyroid hormone b; T4, thyroxine; TH, thyroid hormone; TSH, thyroid-
stimulating hormone; URTI, upper respiratory tract infection.
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decompensation in homozygous or even heterozygous RTHb in which life-threatening hyperthyroid
features predominate.
This article has been published under the terms of the Creative Commons Attribution License (CC
BY; https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in anymedium, provided the original author and source are credited. Copyright for this
article is retained by the author(s).
Freeform/Key Words: cardiac thyrotoxicosis, homozygous THRB mutation, resistance to
thyroid hormone
Thyroid hormones (THs) act via nuclear receptors, encoded by separate genes (THRA, THRB),
with differing tissue distributions (TRa1: central nervous system, myocardium, skeletal
muscle, gastrointestinal tract; TRb1: liver, kidney; TRb2: hypothalamus, pituitary, cochlea,
retina) [1].
Resistance to thyroid hormone b (RTHb), usually due to heterozygousmutations inTHRB,
is characterized by raised TH levels, nonsuppressed thyroid-stimulating hormone (TSH),
and a variable phenotype encompassing both hyperthyroid (e.g., failure to thrive, raised
metabolic rate, tachycardia, low bone mineral density, anxiety) and hypothyroid (e.g., ele-
vated cholesterol) features [2].
Rarely, homozygous RTHb cases occur. Five kindreds, with eight affected individuals,
have been described to date. The first documented RTHb siblings with a homozygous
deletion of THRB [3, 4] exhibited moderately raised TH levels, skeletal abnormalities
(stippled epiphyses, winged scapulae, pectus carinatum), deaf-mutism, and color
blindness; subsequently, patients with a homozygous, single–amino acid deletion [5] and
homozygous [6] or hemizygous [7] missense mutations have been documented. The
clinical phenotype of absent or homozygous mutant TRb is severe, with very elevated TH
levels, marked tachycardia, dysmorphic features, audiovisual abnormalities, and in-
tellectual impairment. Notably, the only death attributable to RTH occurred in a ho-
mozygous RTHb patient, who died of heart failure during an episode of sepsis in
childhood [5, 8].
Here, we describe a 9-year-old, homozygous RTHb child with significantly elevated TH
levels, poor linear growth, and early dilated cardiomyopathy. An older sibling with similar
features died of cardiac failure. A regimen combining antithyroid drug treatment to reduce
TH levels with TRIAC to limit the associated TSH rise, has markedly improved growth and
controlled cardiac dysfunction in our patient.
1. Patient and Methods
A. Case Description
A 9-year-old boy with goiter, tachycardia, and very elevated TH levels with nonsuppressed
TSH levels was investigated.
The proband was born at term, with a low birthweight of 1.9 kg (less than the third
percentile), to consanguineous Arab parents. His neonatal course was unremarkable apart
from a short admission to a neonatal intensive care unit after meconium aspiration. He
had failure to thrive and delayed motor milestones (e.g., walking and speech) during
infancy. He showed signs of early developmental difficulties, including inattention,
restlessness, and impulsivity, with limited awareness of danger, which necessitated high
levels of adult supervision. His vocabulary is limited, and his speech is limited to short
phrases or single words. Schooling is difficult; his reading and writing skills are 2 years
behind those of his peer group.
Additional symptoms include anxiety, insomnia, heat intolerance, and tremor, but appetite
and stool frequency are not increased. Recurrent upper respiratory tract infections (URTIs)
throughout childhood necessitated tonsillectomy (age 9 years). Goiter, noted preoperatively,
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prompted thyroid function tests, showing aTSHof 1.9mU/L (reference range, 0.34 to 4.6), free
thyroxine (FT4). 100 pmol/L (reference range, 12 to 22 pmol/L), and free triiodothyronine of
46.6 pmol/L (reference range, 2.8 to 7.1 pmol/L).
B. Methods
The methods are provided in the Supplemental Data.
2. Results
Clinical features (goiter, hyperactivity, failure to thrive, URTI), together with very elevated
TH and normal TSH levels in the proband, suggested RTHb.
A. Molecular Genetic Studies
THRB sequencing indicated a biallelic nucleotide substitution, corresponding to homo-
zygosity for a recognized RTHb mutation (arginine to glutamine change at codon 243,
R243Q), in the proband. Concordant with being heterozygous for the R243Q TRb mu-
tation, both parents and three siblings exhibited intermediate elevation of TH levels, and
an additional further sibling with normal thyroid function showed wild-type sequence
[Fig. 1(D)].
Figure 1. Phenotypic features of the patient and pedigree. Patient photographs illustrating
thin body habitus (A), dysmorphic facial features (B), and winging of scapula and goiter (C).
Pedigree (D) denoting THRB genotype and thyroid function tests in proband (arrow), siblings,
and parents. Inset photo of deceased older brother, with similar facial features and markedly
elevated thyroid hormone levels, who died of cardiac failure.
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B. Clinical Investigation
Detailed baseline assessment of the proband was undertaken at age 9.25 years. His linear
growth (height, 1.24 m; ,25th percentile) [Fig. 1(A) and 2(B)] and weight (20.1 kg, ,10th
percentile) were subnormal. His resting energy expenditure (0.176 KJ/min per kg lean
body mass) was raised, being 10% above values in age- and sex-matched healthy controls
(n = 15; mean age, 10 years; 0.159 KJ/min per kg). Abnormal skeletal features included a
beaked nose, flattened forehead [Fig. 1(B)], and winging of the scapulae [Fig. 1(C)] Bone
age was disharmonious, being appropriate (phalanges, metacarpals) or delayed (carpal
bones, distal ulna) at different sites (Supplemental Fig. 1) with normal epiphyseal de-
velopment. Whole-body (Z-score, 22.2) and lumbar spine (Z-score, 22.8) areal bone
mineral density by dual x-ray absorptiometry was reduced; high-resolution peripheral
quantitative computed tomography showed marked reduction in trabecular bone volume
at the tibia (Z-score, 24.86) and radius (Z-score, 23.59); this was very evident on three-
dimensional reconstructed images (Supplemental Fig. 1). Ultrasonography confirmed an
enlarged thyroid gland (volume, 19 mL; normal, 6.8 mL in 9-year-old boys [9]) of normal
echotexture without nodularity. Serum thyroglobulin (79 mg/L; normal, 3 to 40 mg/L in
Figure 2. Growth and cardiac responses to treatment. (A) Heart rate (HR) and echocardiographic
parameters (ejection fraction, cardiac index) in the homozygous patient at baseline, 10-month,
and 18-month assessments, compared with healthy child controls, children with heterozygous
RTHb, and children with conventional thyrotoxicosis. Bars represent the range, with
diamonds representing the median. Serial height measurements (B) are plotted on an
ethnically appropriate growth chart. Echocardiographic images in (Ci) and (Cii) show
tricuspid and mitral regurgitation (red arrows), respectively. MRI scans show an enlarged heart
with thinned, dilated LV wall (Cv) (red arrow) and areas of postcontrast myocardial enhancement
(Ciii and Civ) (white arrows) at baseline assessment, with stabilization of LV dilatation and wall
thinning at 18 months (Cvi).
1206 | Journal of the Endocrine Society | doi: 10.1210/js.2017-00204
Downloaded from https://academic.oup.com/jes/article-abstract/1/9/1203/4077039
by University of Cambridge user
on 12 January 2018
healthy boys [10]) was significantly elevated; urinary iodine levels (125.3 mg/L; de-
ficiency , 100 mg/L [9]) were normal.
The proband was functioning in the exceptionally low range in all neuropsychological
domains tested (general intellectual ability, attention, perceptual-motor skills). At a
chronologic age of 9 years, intellectual function was estimated to be equivalent to that seen
at age 4 to 5 years. Reported levels of adaptive behavior were consistent with this. Brain
magnetic resonance imaging (MRI) showed normal parenchyma and pituitary gland. Normal
results were found for visual acuity (right, 6/6; left, 6/9), retinal imaging (fundus photography
and spectral domain optical coherence tomography), and color vision. This last was assessed
clinically by the Ishihara plates, the minimal color test [11], and full-field electroretinography
(normal b-wave amplitude and latencies; Supplemental Fig. 2). Audiometry identifiedmild left-
sided conductive hearing loss (Supplemental Fig. 3), likely due to a prominent jugular bulb
approximating the tympanic membrane (MRI scan, data not shown).
Electrocardiography and 24-hour cardiac telemetry showed sinus tachycardia (heart rate,
125 beats/min); his sleepingheart rate (108 beats/min)was significantly elevated in comparison
with that in most heterozygous RTHb children [Fig. 2(Ai)]. Left ventricular ejection fraction
(74%) and cardiac index (7.56 L/min per m2) were borderline high, with a cardiac index similar
to values seen in childhood thyrotoxicosis [Fig. 2(Aiii)]. His pulmonary artery pressure (39mmHg;
normal , 25 mm Hg) was raised. Echocardiography showed mild tricuspid [Fig. 2C(i)] and
mitral [Fig. 2(Cii)] regurgitation.MRI showed global cardiac enlargement, with left ventricular
(LV) wall thinning [Fig. 2(Cv)]. End-systolic (37 mL/m2; normal, 13 to 30 mL/m2) and end-
diastolic (84mL/m2; normal, 47 to 92mL/m2) LV volumeswere high-normal or raised, with low-
normal systolic function (LV ejection fraction, 56%; normal, 56% to 76% [12]). Postcontrast
imaging showed discrete, basal anteroseptal myocardial enhancement [Fig. 2(Ciii) and 2(Civ)],
suggesting focal increased tissue permeability or edema. Circulating N-terminal pro B-type
natriuretic peptide (NT proBNP) concentrations (298 pg/mL; median in healthy children age 6
to 14 years, 52 pg/mL [13]) were elevated.
C. Family History
An older brother, who died at age 13 years, had a remarkably similarmedical history, with low
birthweight and meconium aspiration neonatally, recurrent childhood URTIs requiring
tonsillectomy, hyperactivity, and thin body habitus and facial features [Fig. 1(D)] resembling
those in our patient. At age 11 years, he developed dyspnea, mitral regurgitation, and cardiac
failure refractory to digoxin and diuretic therapy. His thyroid function (tested because of
palpitations and sweating) was grossly abnormal [TSH, 0.14 mU/L; FT4. 6 ng/dL (reference
range, 0.71 to 1.85ng/dL); free triiodothyronine, 25.7pg/mL (reference range, 1.45 to 3.48pg/mL)].
Echocardiography documented left atrial and ventricular dilatation, and he died despite diuretic
and later antithyroid drug treatment.
D. Response to Therapy
Our patient was treated with a combination of carbimazole and TRIAC over 26months. Beta-
blockade (atenolol, 50 mg daily) was also instituted but was discontinued for 72 hours before
major assessments (baseline and 10, 18, and 26 months after treatment), which included
serial biochemical and physiologic parameters, echocardiography, cardiac MRI, and thyroid
ultrasonography.
D-1. Thyroid axis
During the first 14 months of treatment, FT4 levels fell markedly, from 133 to 14 pmol/L,
with a concomitant rise in TSH, which peaked at 39 mU/L; subsequent titration of carbi-
mazole and TRIAC achieved better, stable thyroid function (FT4, 35 pmol/L; TSH, 3.5mU/L;
Fig. 3).
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D-2. Growth and clinical response
His height velocity improved, with stature (1.39 m) crossing to between the 25th and 50th
percentiles [Fig. 2(B)]. Improved concentration and diminished hyperactivity were reflected
in improved school behavior and social skills.
D-3. Cardiac function
The patient’s sleeping heart rate fell from 108 to 72 beats/min. Echocardiographic indices
deteriorated at the 10-month assessment, while FT4 remained at .60 pmol/L (ejection
Figure 3. Changes in biochemical and physiologic parameters following treatment. Top bar
charts denote carbimazole (CBZ) and TRIAC dosage, superimposed on a graph of serial FT4
and TSH levels over 26 months of treatment. At bottom, physiologic and biochemical
parameters are tabulated at 0 (baseline) and 10, 18, and 26 months, with serial transverse
thyroid ultrasonographic images and computed gland volume at similar time points. HR,
heart rate; LBM, lean body mass; LDL, low-density lipoprotein; ND, not determined; REE,
resting energy expenditure; SHBG, sex hormone–binding globulin.
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fraction: baseline, 74% to 53% at 10 months; stroke volume index: baseline, 7.56 to 3.5 L/min
perm2 at 10months), but with lower FT4 levels (15 to 40 pmol/L) over the following 8months,
these parameters improved and stabilized (18 months: ejection fraction, 68%; cardiac index,
6.5 L/min per m2). Cardiac MRI showed an increase in LV mass (45 g at baseline to 53 g at
26 months) with absence of previous postcontrast LV wall enhancement [Fig. 2(Cvi)]. His
circulating NT-proBNP levels fell from 298 to 125 pg/mL.
D-4. Metabolic response
Reduction in resting energy expenditure (baseline, 0.1756 to 0.166 KJ/min per kg at
26 months), was associated with substantial gain in lean body mass (16.9 kg at baseline and
21.0 kg at 26 months). Serum total cholesterol (3.1 mmol/L at baseline and 3.3 mmol/L at
26 months), low-density lipoprotein cholesterol (1.53 mmol/L at baseline and 1.58 mmol/L
at 26months), and sex hormone–binding globulin (71.9 nmol/L at baseline and 78.6mmol/L at
26 months) have not risen substantially.
D-5. Goiter
The patient’s thyroid volume increased (19mLat baseline and 59mLat 18months) but is now
stabilized (63 mL at 26 months); notably, there are no compressive features, and the texture
remains nonnodular.
3. Discussion
We describe a patient with homozygous RTHb, making a total of nine individuals with this
rare condition reported worldwide. Similar to previous homozygous RTHb cases, our patient
exhibits an extreme phenotype compared with heterozygotes; the patient had FT4 6.5-fold
above the upper limit of normal, as well as marked tachycardia, early cardiomyopathy and
reduced trabecular bone volume. His dysmorphic facial features and winged scapulae re-
semble those in severe heterozygous [14] or homozygous RTHb patients [3, 6].
TH levels are more markedly elevated in RTHb patients harboring homozygous mutant
TRb vs. deletion of THRB [6], suggesting that dominant negative inhibition by mutant TRb
mediates greater resistance within the hypothalamic-pituitary-thyroid feedback axis.
Computing a thyroxine (T4) resistance index (fold elevation of FT4 multiplied by TSH) in
patients quantifies the degree of axis resistance [6]; compared with other homozygous RTHb
cases (T4 resistance index of 4900 to 239,120), this patient’s T4 resistance index (836) is
unusually low. TRb2 is also important for normal audiovisual development [15, 16]; the first
homozygousTHRB null cases exhibited profound sensorineural deafness andwere color blind
[3]. Hearing loss was noted in other homozygous cases [6].
Similar to TRb2 null mice, reduced retinal L- and M- and increased S-cone function has
been documented in an RTHb patient with compound heterozygous TRb mutations [17].
Monochromacy with abnormal photopic electroretinogram (ERG) was recorded in a homo-
zygousTHRB null case [18]. Normal clinical testing and full-field photopic ERG in our patient
exclude a major abnormality in color vision. However, because of his young age, we did not
obtain specialized ERG aimed at evaluating specific cone subtypes [17, 19], such that mild,
cone subtype–specific dysfunction cannot be discounted.
The combination of unimpaired color vision, normal hearing, and relatively low T4
resistance index in our patient raises the possibility that these target tissues are less
refractory to TH action than in other homozygous RTHb cases. It is tempting to speculate
that this might be due to unique functional properties of the R243Q mutation in the TRb
background.
When studied in the TRb1 context, the R243Q mutant exhibits normal triiodothyronine
binding in solution; however, when bound toDNA, triiodothyronine-dependent dissociation of
mutant receptor homodimers or release of corepressor is markedly impaired [20, 21]. This
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suggests that the receptor DNA–binding domain can modulate function of the hormone-
binding domain via allosteric mechanisms.
Byanalogy, it is tempting to speculate thatbyallostericallymodulating transcriptional function
of its divergent aminoterminal domain, the R243Q mutation is less deleterious in the TRb2
background, thus accounting for absent or milder phenotypes in TRb2-expressing target tissues.
This study used in vivo Xtreme CT (Scanco Medical, Zurich, Switzerland) to examine the
bones of children with RTHb. This technique permits the evaluation of the crucial trabecular
compartment and unlike dual x-ray absorptiometry is not influenced by bone or body size. In
this case, it was apparent that RTHb was strongly linked with low trabecular bone mass
rather than cortical bone mass; this observation is consistent with defective mineralization
documented in homozygous TRb null mice [22].
Thyrotoxicosis reduces peripheral vascular resistance, induces tachycardia, and raises
stroke volume [23]; the raised cardiac output and higher baseline cardiac index in our proband
may reflect this.However, in chronic hyperthyroidism, inability to further increase heart rate,
increase ejection fraction, or reduce systemic vascular resistance diminishes cardiac function
[24] and other stressors (e.g., sepsis); atrial fibrillation–mediated reduction in cardiac output
or development of pulmonary hypertension can cause “decompensation” and cardiac failure
[25]. Indeed, one homozygous RTHb case, harboring a D337T mutant TRb [5], died of cardiac
failure in the context of systemic sepsis (Barry B. Bercu, personal communication). With
marked similarities between the proband and his deceased older brother, we hypothesize that
his sibling also had homozygousRTHb and developed heart failure following cardiac exposure
to chronic hyperthyroxinemia. Thus, we sought to prevent similar TH-mediated cardiac
toxicity in our patient. In this context, we reasoned that beta-adrenergic receptor blockade,
reducing the chronotropic component but not the inotropic drive associated with cardiac
hyperthyroidism, would be insufficient. Definitive treatment (e.g., surgical or radioiodine
thyroid ablation) of our patient was considered but has risks in this context. After surgery,
ongoing TSH stimulation in RTHb prompts regrowth of remnant thyroid tissue. Thyroid
ablation may require multiple, higher doses of radioiodine, with attendant risk for radiation
thyroiditis–mediated TH release from the gland, precipitating thyroid storm and cardiac
decompensation. Following thyroid ablation, pituitary hyperplasia does occur in RTHb [26],
necessitating supraphysiologic thyroid hormone replacement to avoid this, but at the cost of
restoring very elevated, preablation TH levels. Furthermore, no definitive criteria guide ti-
tration of postablative T4 replacement in RTHb The risk for suboptimal TH treatment in this
childhood case is deleterious for growth, development, and neurocognition.
Although antithyroid drugs decrease TH levels effectively in conventional thyrotoxicosis,
such reduction in RTHb cases causes exaggerated TSH elevation, overriding blockade of
hormone biosynthesis and inducing goiter formation. To circumvent this, we treated our
patient with TRIAC, a centrally acting TH analog known to be effective in themanagement of
childhood RTHb [27–29]. This agent inhibits TSH secretion and lowers TH levels yet is
relatively devoid of peripheral thyromimetic activity. Because of the magnitude of hyper-
thyroxinemia, TRIAC therapy alone failed to lower TH levels sufficiently. Addition of car-
bimazole progressively normalized FT4 levels, but this normalization was accompanied by a
substantial TSH rise, with associated increase in thyroid volume (Fig. 3). Further titration of
antithyroid drugs and TRIAC achieved moderate hyperthyroxinemia with normal TSH
levels, reflected in lower metabolic rate, weight gain with higher lean mass, and improved
growth. Increase in thyroid volume is a concern, and ongoing, regular sonographic surveil-
lance is planned, both to assess whether the goiter has stabilized and to verify that the gland
remains nonnodular, particularly as follicular tumors have been documented in homozygous
TRb mutant mice [30].
Initial findings (tachycardia, raised cardiac index, preserved ejection fraction) in our
patient were consistent with thyrotoxic cardiac status. However, significantly raised NT-
proBNP levels reflected increased ventricular strain, and abnormal enhancement on MRI
suggests localized myocardial edema (Fig. 2), which together raised the possibility of early
dilated cardiomyopathy [31]. In that context, deterioration in cardiac index and ejection
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fraction in the patient, when assessed at 10 months after therapy [but with significantly
elevated FT4 (.60 pmol/L)], suggested that cardiac decompensation might ensue. However,
following further and sustained reduction in TH levels (,40 pmol/L), the patient’s echo-
cardiographic indices (cardiac index, ejection fraction) have improved significantly, with
increased LVmass and resolution of abnormal enhancement onMRI. These changes indicate
stabilization or reversal of cardiomyopathy with restored normal cardiac output.
If cardiac function and metabolic parameters remain well controlled on this combination
treatment regimen, with prevention of hyperthyroid cardiomyopathy and its decompensation
in the long term, we suggest that such therapy may be a useful alternative to thyroid ablation
in other homozygous or even some heterozygous RTHb cases in which severe, potentially life-
threatening hyperthyroid features predominate. Thyroidectomy, with subsequent T4 and
TRIAC treatment, could be considered if the patient develops worsening heart failure or
compressive symptoms due to goiter.
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